Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN
Eledon Pharmaceuticals — Technical Presentation (November 2023)
15 slides from Eledon Pharmaceuticals's technical presentation, Nov 2, 2023
Slide 1: Phase 1b Trial Update: Evaluating Tegoprubart For The Prevention of Rejection In Kidney Transplantation
Phase 1b Trial Update: Evaluating Tegoprubart For The Prevention of Rejection In Patients Undergoing Kidney Transplantation November 2, 2023 EXHIBIT 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements that involves substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about its strategy, future operations, development of its product cand
Slide 3: Tegoprubart: Transplantation Focused Pipeline in a Product Opportunity
Tegoprubart: Transplantation Focused Pipeline in a Product Opportunity Note: As of September 22, 2023. Development plans and timelines may change, including based on US and global regulatory interactions. Indications DEVELOPMENT STAGE Pre-clinical Phase 1 / Early Human Trials Phase 2 Phase 3 Kidney
Slide 4: Kidney Transplantation Immunosuppression Market Represents a Multi-Billion Dollar Commercial Opportunity
Kidney Transplantation Immunosuppression Market Represents a Multi-Billion Dollar Commercial Opportunity Large Patient Population Sources: NIDDK; USRDS; DHHS OPTN; Milliman 2020; Statista 2021; Astellas; Novartis; Precision Reports 2023. End Stage Renal Disease & Transplant Medicare covers cost of i
Slide 5: Mechanism Overview of CD40L Inflammatory Signaling
Mechanism Overview of CD40L Inflammatory Signaling Interaction of CD40 with CD40L on immune cells mediates activation of the co-stimulatory immune pathway, controlling "cross talk” between the adaptive and innate immune systems Maximal activation of inflammatory system is a 3-step process requiring
Slide 6: Removing CNIs May Stop the Cycle of Transplantation and Subsequent CNI Related Graft Failure
Removing CNIs May Stop the Cycle of Transplantation and Subsequent CNI Related Graft Failure Source: Nankivell 2003; ATC 2018; NIDDK; USRDS; DHHS OPTN; Milliman 2020; Statista 2021; Astellas; Novartis; Precision Reports 2023; UCSF.. CNI side effects are a leading cause of kidney graft failure over t
Slide 7: Distribution of eGFRs Using Standard of Care Post Transplant
Distribution of eGFRs Using Standard of Care Post Transplant: Median ~51 mL/min/1.73m2 in First Year Source: Am J Kidney Dis. 2011 Mar; 57(3):466-75.
Slide 8: Kidney Allograft Function is an Early Predictor of Future Graft Failure
Kidney Allograft Function is an Early Predictor of Future Graft Failure eGFR at 12 months is associated with subsequent death-censored graft failure Source: Am J Kidney Dis. 2011 Mar; 57(3):466-75. Graft function measured using eGFR at 12 months post transplant is associated independently with subse
Slide 9: Phase 1b and Phase 2 Kidney Transplantation Studies are Running in Parallel
Phase 1b and Phase 2 Kidney Transplantation Studies are Running in Parallel Note: Development plans may change, including based on US and global regulatory interactions. Phase 1b Up to 12 participants undergoing kidney transplantation Canada, UK and Australia 52-week, open label, single arm study Ph
Slide 10: Kidney Transplantation: Demographics & Disposition
Phase 1b Kidney Transplantation: Demographics & Disposition Source: ASN, November 2, 2023.
Slide 11: Kidney Transplantation: Treatment Emergent Adverse Events
Phase 1b Kidney Transplantation: Treatment Emergent Adverse Events Source: ASN, November 2, 2023. 1 participant experienced a T cell mediated rejection (Banff score 1a). The patient was treated and remains in the study 1 patient experienced a surgical related acute tubular necrosis on day 0 (prior t
Slide 12: Kidney Transplantation: Mean eGFR Over Time
Phase 1b Kidney Transplantation: Mean eGFR Over Time Pro-Inflammatory CD40L Target Engagement Note: Estimated glomerular filtration rate (eGFR) as of October 19, 2023, calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) creatinine equation. N is the number of participant
Slide 13: Kidney Transplantation: Summary Conclusions
Phase 1b Kidney Transplantation: Summary Conclusions Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90, supporting teg
Slide 14: Q&A
Q&A 14
Slide 15: Eledon Pharmaceuticals contact details
Eledon Pharmaceuticals 19900 MacArthur Blvd., Suite 550 Irvine, California 92612, USA info@eledon.com +1 949-238-8090
Eledon Pharmaceuticals — Technical Presentation (November 2023) on 6ix